Hypertension Clinical Trial
Official title:
Examining the Individual Response to a Restricted Sodium Diet in Hypertensive Patients
Verified date | June 2024 |
Source | The University of Texas Health Science Center at San Antonio |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Excessive dietary sodium intake is an independent risk factor for hypertension and cardiovascular disease. A vast array of efforts have tried to reduce sodium consumption based on evidence indicating a public health benefit. Yet this benefit has been questioned, mainly based on studies showing variability in individual responses to a sodium-restricted diet (SRD). The effects of an SRD on blood pressure vary, and adherence to an SRD is not optimal. The original Sodium Watchers Program (R01NR012967) was developed and implemented by Dr. Misook Chung (University of Kentucky). In this pilot study, the modified Sodium Watchers Program will propose improving adherence to an SRD through education and digital self-monitoring for daily sodium intake and blood pressure. In addition, few studies have examined individuals' metabolic responses to the SRD. In a secondary analysis, we further will examine genetic variants associated with salt sensitivity and whether such a genetic component is associated with sodium excretion and BP control. A total of 40 hypertensive patients will be randomly assigned to the intervention (n=20) or control group (n=20). The intervention group will receive 8-week education sessions remotely using a video conferencing program. All participants will collect a 24-hour urine specimen for sodium excretion and a total of 4.0ml of peripheral blood will be drawn for salt sensitivity during baseline visit. All participants will be asked to log their activities in real-time, including food intake and in-home BP monitoring using Fitbit and accompanied mobile app and BP monitor.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: - Systolic blood pressure of 120-159 mmHg or diastolic blood pressure of 80-99 mmHg, whether or not taking blood pressure medications. - Smartphone with a data plan - Valid email address - Willing and able to participate in online study videoconferencing visits (Zoom) - Reads and writes in English Exclusion Criteria: - Participating in another related research study - Cardiovascular disease event (e.g. stroke, myocardial infarction) in prior 6 months - Active cancer - Recent hospitalization due to psychiatric condition or event - Pregnancy or breastfeeding - current or planned during the study period - Documented dementia - Prisoners - Diabetes Diagnosis - Heart Failure Diagnosis |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center at San Antonio | National Center for Advancing Translational Sciences (NCATS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in blood pressure over time | Blood pressure (BP) will be measured using a Vital Signs Monitor 300 Series model (WelchAllyn, US). The midsection circumference of the dominant upper arm will be measured with a tape measure, and the proper sized cuff will be selected accordingly. Systolic and diastolic BP will be measured in the dominant arm twice with a 2-minute rest period between measures; two measures will be averaged. | Up to 8 weeks | |
Primary | Change in adherence to sodium restricted diet over time | Participants will complete a 24-hour urinary sodium excretion test at baseline and at 8 weeks after the intervention is completed. 24-hour urinary sodium excretion (mg excreted/day) will be tested by collecting all urine excreted over 24 hours. Participants are asked to note the time when they start in a written log, then discard the first urine after that time. They will then collect all urine excreted over the course of the next 24 hours, noting down the time and amount excreted each time in the written log. Urine is stored in a container and does not need refrigeration. 24-hour urine sodium samples will be analyzed by the Center for Renal Precision Medicine laboratory. | Up to 8 weeks | |
Secondary | Adherence to dietary sodium intake monitoring | Adherence to dietary sodium intake monitoring will be monitored using Fitbit companion mobile dietary app. The Fitbit app is intended as an intervention tool to enhance self-monitoring and promote adherence, not a reliable assessment tool for dietary sodium intake (24-hour urinary samples will be used for that purpose as described in outcomes section). Each subject will be registered to assign a unique ID in the platform developed by the Center on Smart and Connected Health Technologies at UT Health San Antonio, and each account from the individuals' Fitbit will be connected to his or her unique ID through this platform. Subjects will be instructed to log their food intake in real-time. Percentage of days that subject log his or her meal in the dietary app with a calorie intake of over 1000 will be used to measure adherence to dietary sodium intake monitoring. | Up to 8 weeks | |
Secondary | Adherence to In-home BP monitoring | Adherence to In-home BP monitoring will be measured by the percentage of days that subject log in-home BP using a wireless and automatic BP monitor device (Omron 7 Series Upper Arm BP Monitor). It has a range of 0 to 299 mmHg for BP and 40 to 180 beats per minute (bpm) for heart rate (HR). The cuff is inflated using an electric pump and deflated by means of a pressure release valve. After each measurement, the SBP, DBP, and HR are shown on the LCD screen. The device can also display a symbol on the screen indicating an irregular heartbeat detected during measurement of SBP and DBP. Each subject will be registered to assign a unique ID in the Connected Health Platform and each account from the individuals' Omron mobile app will be connected to his or her unique ID through this platform. Subjects will be instructed to measure BP while in a sitting position and transfer the BP data to Omron mobile app using a wireless and automatic BP monitor device. | Up to 8 weeks | |
Secondary | Attendance at education sessions | Attendance at education sessions will be measured by number of attended sessions for the 8-week education sessions in intervention group. | Up to 8 weeks | |
Secondary | Retention rate | Retention rate will be measured by the percentage of subjects who come to the follow-up visit (8 weeks). | Up to 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |